JP2020520988A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520988A5
JP2020520988A5 JP2020504095A JP2020504095A JP2020520988A5 JP 2020520988 A5 JP2020520988 A5 JP 2020520988A5 JP 2020504095 A JP2020504095 A JP 2020504095A JP 2020504095 A JP2020504095 A JP 2020504095A JP 2020520988 A5 JP2020520988 A5 JP 2020520988A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
optionally
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020504095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520988A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026014 external-priority patent/WO2018187423A1/en
Publication of JP2020520988A publication Critical patent/JP2020520988A/ja
Publication of JP2020520988A5 publication Critical patent/JP2020520988A5/ja
Priority to JP2023101616A priority Critical patent/JP7781821B2/ja
Priority to JP2025203641A priority patent/JP2026041812A/ja
Pending legal-status Critical Current

Links

JP2020504095A 2017-04-05 2018-04-04 タンパク質−タンパク質界面を分析するための方法及び試薬 Pending JP2020520988A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023101616A JP7781821B2 (ja) 2017-04-05 2023-06-21 タンパク質-タンパク質界面を分析するための方法及び試薬
JP2025203641A JP2026041812A (ja) 2017-04-05 2025-11-26 タンパク質-タンパク質界面を分析するための方法及び試薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482018P 2017-04-05 2017-04-05
US62/482,018 2017-04-05
PCT/US2018/026014 WO2018187423A1 (en) 2017-04-05 2018-04-04 Methods and reagents for analyzing protein-protein interfaces

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023101616A Division JP7781821B2 (ja) 2017-04-05 2023-06-21 タンパク質-タンパク質界面を分析するための方法及び試薬

Publications (2)

Publication Number Publication Date
JP2020520988A JP2020520988A (ja) 2020-07-16
JP2020520988A5 true JP2020520988A5 (https=) 2021-05-13

Family

ID=63712343

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020504095A Pending JP2020520988A (ja) 2017-04-05 2018-04-04 タンパク質−タンパク質界面を分析するための方法及び試薬
JP2023101616A Active JP7781821B2 (ja) 2017-04-05 2023-06-21 タンパク質-タンパク質界面を分析するための方法及び試薬
JP2025203641A Pending JP2026041812A (ja) 2017-04-05 2025-11-26 タンパク質-タンパク質界面を分析するための方法及び試薬

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023101616A Active JP7781821B2 (ja) 2017-04-05 2023-06-21 タンパク質-タンパク質界面を分析するための方法及び試薬
JP2025203641A Pending JP2026041812A (ja) 2017-04-05 2025-11-26 タンパク質-タンパク質界面を分析するための方法及び試薬

Country Status (11)

Country Link
US (2) US20210285955A1 (https=)
EP (1) EP3607326A4 (https=)
JP (3) JP2020520988A (https=)
KR (2) KR20240093922A (https=)
CN (1) CN110785428A (https=)
AU (2) AU2018250186B2 (https=)
BR (1) BR112019020967A2 (https=)
CA (1) CA3058964A1 (https=)
IL (2) IL269779B2 (https=)
MX (1) MX2025014195A (https=)
WO (1) WO2018187423A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
KR20210116479A (ko) * 2018-12-21 2021-09-27 레볼루션 메디슨즈, 인크. 공동 결합에 참여하는 화합물 및 그의 용도
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119661684B (zh) * 2024-10-21 2025-11-25 山东大学 一种高抗炎活性的脂联素突变体及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010373A1 (en) * 1997-08-26 1999-03-04 Wisconsin Alumni Research Foundation Non-immunosuppressive cyclosporins and their use in the prevention and treatment of hiv infection
US7220552B1 (en) * 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
EP1968583A4 (en) * 2005-12-20 2010-09-15 Harvard College COMPOUNDS, SCREENING AND TREATMENT PROCEDURES
CA2636075C (en) * 2006-01-03 2011-11-08 F. Hoffmann-La Roche Ag Chimaeric fusion protein with superior chaperone and folding activities
US20090054334A1 (en) * 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
US9428845B1 (en) * 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
WO2012174489A2 (en) * 2011-06-15 2012-12-20 The Ohio State University Small molecule composite surfaces as inhibitors of protein-protein interactions
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
US10427131B2 (en) * 2015-03-19 2019-10-01 3M Innovative Properties Company Guanidine-functionalized perlite particles, articles containing the particles, and methods of using the particles and articles
WO2017059207A1 (en) * 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CN105902537A (zh) * 2016-04-26 2016-08-31 兰州大学 靶向人fkbp51蛋白的先导化合物及其筛选方法与应用
AU2018248417A1 (en) * 2017-04-05 2019-11-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof

Similar Documents

Publication Publication Date Title
JP2020520988A5 (https=)
JP2019501863A5 (https=)
JP2023052201A5 (https=)
US20220403052A1 (en) Anti-dll4/vegf dual variable domain immmunoglobulin and uses thereof
Yang et al. Getting across the cell membrane: an overview for small molecules, peptides, and proteins
JP2021531826A5 (https=)
ES2856482T3 (es) Combinaciones de inhibidores de FGFR y cMet para el tratamiento del cáncer
SG11201408279QA (en) Social sharing of security information in a group
JP2015508757A5 (https=)
JP2017506505A5 (https=)
Koepsell Substrate recognition and translocation by polyspecific organic cation transporters.
JP2021533166A5 (https=)
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
JP2014504622A5 (https=)
UA124529C2 (uk) Модулятори екто-5-нуклеотидази та їх застосування
HRP20180443T1 (hr) Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe
Gunnam et al. Salts and salt cocrystals of the antibacterial drug pefloxacin
HRP20171777T1 (hr) Novi himerni polipeptidi za potrebe probira i otkrivanja lijekova
EP2650009A3 (en) Screening methods using G-protein coupled receptors and related compositions
CA2955554C (en) Methods to select for agents that stabilize protein complexes
WO2012012531A3 (en) Compositions and methods featuring il-6 and il-21 antagonists
WO2016115218A1 (en) Antibody drug conjugates for the treatment of immune conditions
Zhou et al. Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects
CA2944462A1 (en) Novel hdmx inhibitors and their use for cancer treatment
JP2021505578A5 (https=)